ClinicalTrials.gg
CompletedNCT02099110Updated Sep 12, 2018Results posted

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

A Phase 3 interventional study of Matching Placebo to Ertugliflozin 5 mg and Matching Placebo to Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,233
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
3rd of 28
1,233 · median 83
Started
2014
with 3 others
Phase 3
11 of 28
none open now
Registered
14th of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 14th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.

Read the detailed description

This study will include a 1-week screening period; an up to 12-week metformin titration/dose stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14 days after the last dose of study medication.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus as per American Diabetes Association guidelines
  • On metformin monotherapy (>=1500 mg/day) for >=8 weeks with a Visit 1/Screening >=7.5% and \<=11.0% (>=58 mmol/mol and \<=97 mmol/mol) OR On metformin monotherapy (>=1500 mg/day) for \<8 weeks with a Visit 1/Screening A1C >=7.5% and \<=11.0% (>=58 mmol/mol and \<=97 mmol/mol) OR On metformin monotherapy \<1500 mg/day with a Visit 1/Screening A1C >=8.0% and \<=11.5% (>=64 mmol/mol and \<=102 mmol/mol)
  • (BMI) >=18.0 kg/m\^2
  • Male or female not of
  • Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes mellitus or ketoacidosis
  • History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant
  • A known or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor or sitagliptin
  • Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use [i.e., \<=7 days] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset™), colesevelam (Welchol™), any other antihyperglycemic agents (AHA) with the exception of the protocol-approved agents
  • Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start
  • Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable prior to study start
  • A history of myocardial infarction, unstable angina, arterial revascularization, stroke, , or (NYHA) functional class III-IV heart failure within 3 months of study start
  • Active, obstructive uropathy or indwelling urinary catheter
  • History of \<=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • A known history of (HIV)
  • A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Any clinically significant malabsorption condition
  • Current treatment for hyperthyroidism
  • On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start
  • On a previous clinical study with ertugliflozin
  • Estimated (eGFR) (using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD) equation) \<60 mL/min/1.73 m\^2
  • Serum creatinine >= 1.3 mg/dL (115 µmol/L) for males and >= 1.2 mg/dL (106 µmol/L) for females
  • (ALT) or aspartate aminotransferase (AST) >2 times
  • \<12 g/dL (120 g/L) for males and \<11 g/dL (110 g/L) for females.
  • Participated in other studies involving drug(s) 30 days prior to study start
  • Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial
  • Positive urine pregnancy test
  • Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication
  • Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking
  • Donated blood or blood products within 6 weeks of study start
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,233 participants (actual)

Study arms

  • Experimental
    Ertugliflozin 5 mg + sitagliptin 100 mg

    Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks

    Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Ertugliflozin 5 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication

  • Experimental
    Ertugliflozin 15 mg + sitagliptin 100 mg

    Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks

    Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication

  • Experimental
    Ertugliflozin 5 mg

    Ertugliflozin 5 mg, oral, once daily for 52 weeks

    Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Matching Placebo to sitagliptin 100 mg · Drug: Ertugliflozin 5 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication

  • Experimental
    Ertugliflozin 15 mg

    Ertugliflozin, oral, once daily for 52 weeks

    Drug: Matching Placebo to sitagliptin 100 mg · Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication

  • Active comparator
    Sitagliptin 100 mg

    Sitagliptin 100 mg, oral, once daily for 52 weeks

    Drug: Matching Placebo to Ertugliflozin 5 mg · Drug: Matching Placebo to Ertugliflozin 10 mg · Drug: Sitagliptin 100 mg · Drug: Metformin >= 1500 mg/day · Biological: Insulin Glargine Rescue Medication · Drug: Glimepiride Rescue Medication

Interventions

  • DrugMatching Placebo to Ertugliflozin 5 mg

    Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • DrugMatching Placebo to Ertugliflozin 10 mg

    Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • DrugMatching Placebo to sitagliptin 100 mg

    Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

  • Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

    Also known as: MK-8835, PF-04971729

  • Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

    Also known as: MK-8835, PF-04971729

  • Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period

    Also known as: JANUVIA®

  • DrugMetformin >= 1500 mg/day

    Drug page: Metformin

    Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period

    Also known as: Glucophage, Glucophage XR

  • Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion

    Also known as: Lantus

  • Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion

    Also known as: AMARYL

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 26: Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  2. Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.

    Time frame: Up to 54 weeks

  3. Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach

    This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  2. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach

    Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

  3. Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach

    A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Week 26

  4. Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach

    Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\] and model-based \[beta cell function and insulin secretion rate at 9 mM glucose\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\^-9 min\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: 30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26

  5. Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach

    This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

    Time frame: Baseline and Week 26

07

Results

Posted Nov 1, 2017

Participant flow

The trial was conducted in 21 countries and included 242 trial centers.

Participant flow — Overall Study
MilestoneErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Started250248247243245
Treated250248247243244
Completed226217219221218
Not completed2431282227
Withdrew: Protocol violation21031
Withdrew: Participant moved11102
Withdrew: Withdrawal by subject71113913
Withdrew: Adverse event35232
Withdrew: Lost to follow-up6121156
Withdrew: Death01000
Withdrew: Screen failure00001
Withdrew: Non-compliance with study drug20001
Withdrew: Physician decision30121

Outcome measures

PrimaryChange From Baseline in A1C at Week 26: Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Percentage
Change From Baseline in A1C at Week 26: Excluding Rescue Approach
PercentageErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Change From Baseline in A1C at Week 26: Excluding Rescue Approach-1.02 (-1.14 to -0.90)-1.08 (-1.20 to -0.96)-1.05 (-1.17 to -0.93)-1.49 (-1.61 to -1.36)-1.52 (-1.64 to -1.40)
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = <0.001 (Constrained longitudinal data analysis (cLDA) model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.46 · 95% CI -0.63 to -0.30
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = <0.001 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.43 · 95% CI -0.60 to -0.27
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = <0.001 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.44 · 95% CI -0.61 to -0.27
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = <0.001 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -0.47 · 95% CI -0.63 to -0.30
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.

Time frame:
Up to 54 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach62.057.757.558.855.7
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Difference in % vs ertugliflozin 5 mg: -3.2 · 95% CI -11.7 to 5.5Based on Miettinen \& Nurminen method.
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Difference in % vs. ertugliflozin 15 mg: -1.9 · 95% CI -10.6 to 6.8Based on Miettinen \& Nurminen method.
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Difference in % vs. sitagliptin 100 mg: 1.4 · 95% CI -7.4 to 10.1Based on Miettinen \& Nurminen method.
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Difference in % vs. sitagliptin 100 mg: -1.8 · 95% CI -10.5 to 7.0Based on Miettinen \& Nurminen method.
PrimaryPercentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach3.23.22.83.33.7
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Difference in % vs. ertugliflozin 5 mg: 0.1 · 95% CI -3.3 to 3.6Based on Miettinen \& Nurminen method.
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Difference in % vs. ertugliflozin 15 mg: 0.5 · 95% CI -3.0 to 4.0Based on Miettinen \& Nurminen method.
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Difference in % vs. sitagliptin 100 mg: 0.5 · 95% CI -2.9 to 3.9Based on Miettinen \& Nurminen method.
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Difference in % vs. sitagliptin 100 mg: 0.9 · 95% CI -2.5 to 4.4Based on Miettinen \& Nurminen method.
SecondaryChange From Baseline in Body Weight at Week 26: Excluding Rescue Approach

This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Kilograms
Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
KilogramsErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach-2.69 (-3.13 to -2.25)-3.74 (-4.18 to -3.29)-0.67 (-1.12 to -0.22)-2.52 (-2.97 to -2.07)-2.94 (-3.39 to -2.49)
Statistical analysis
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = <0.001 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -1.85 · 95% CI -2.48 to -1.22
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Constrained logitudinal data analysis · p = <0.001 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -2.27 · 95% CI -2.90 to -1.64
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach

Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
mg/dLErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach-35.73 (-40.04 to -31.42)-36.91 (-41.21 to -32.62)-25.56 (-29.93 to -21.19)-43.96 (-48.29 to -39.63)-48.70 (-53.01 to -44.39)
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · cLDA · p = 0.004 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -8.23 · 95% CI -13.82 to -2.65
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · cLDA · p = <0.001 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -11.79 · 95% CI -17.35 to -6.23
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · cLDA · p = <0.001 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -18.40 · 95% CI -24.03 to -12.77
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · cLDA · p = <0.001 (cLDA model including fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -23.14 · 95% CI -28.76 to -17.53
SecondaryPercentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach

A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
Percentage of participantsErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach26.431.932.852.349.2
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Regression, Logistic · p = <0.001 (Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.) · Odds ratio (or): 4.14 · 95% CI 2.68 to 6.40
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Regression, Logistic · p = <0.001 (Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.) · Odds ratio (or): 2.53 · 95% CI 1.68 to 3.83
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Regression, Logistic · p = <0.001 (Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.) · Odds ratio (or): 2.95 · 95% CI 1.92 to 4.54
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.56 · 95% CI 1.69 to 3.89Adjusted Odds Ratio using a logistic regression model fitted with fixed effects for treatment, covariates for baseline A1C and baseline eGFR.
SecondaryChange From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach

Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L \* L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based \[including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC\] and model-based \[beta cell function and insulin secretion rate at 9 mM glucose\] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10\^-9 min\^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26
Reported as:
Least squares mean · SBCSGI (10^-9min^-1)
Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
SBCSGI (10^-9min^-1)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach8.62 (1.28 to 15.96)9.71 (2.29 to 17.13)21.11 (13.55 to 28.67)16.24 (8.36 to 24.11)11.51 (3.76 to 19.26)
Statistical analysis
  • Ertugliflozin 5 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = 0.155 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: 7.61 · 95% CI -2.90 to 18.13
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = 0.369 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -4.87 · 95% CI -15.54 to 5.80
  • Ertugliflozin 15 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = 0.734 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: 1.81 · 95% CI -8.66 to 12.27
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Difference in the least squares means · p = 0.075 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -9.59 · 95% CI -20.17 to 0.98
SecondaryChange From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach

This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · mm Hg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
mm HgErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach-3.89 (-5.28 to -2.50)-3.69 (-5.08 to -2.30)-0.66 (-2.07 to 0.76)-3.42 (-4.82 to -2.03)-3.67 (-5.06 to -2.29)
Statistical analysis
  • Sitagliptin 100 mg vs Ertugliflozin 5 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = 0.005 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -2.76 · 95% CI -4.69 to -0.83
  • Sitagliptin 100 mg vs Ertugliflozin 15 mg + Sitagliptin 100 mg · Constrained longitudinal data analysis · p = 0.002 (cLDA model with fixed effects for treatment, time, baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.) · Difference in the least squares means: -3.01 · 95% CI -4.94 to -1.09

Adverse events

Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ertugliflozin 5 mg—12/250 (4.8%)36/250 (14.4%)
Ertugliflozin 15 mg—5/248 (2%)43/248 (17.3%)
Sitagliptin 100 mg—8/247 (3.2%)28/247 (11.3%)
Ertugliflozin 5 mg + Sitagliptin 100 mg—9/243 (3.7%)31/243 (12.8%)
Ertugliflozin 15 mg + Sitagliptin 100 mg—12/244 (4.9%)38/244 (15.6%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
Acute myocardial infarctionCardiac disorders1/2500/2481/2470/2432/244
VomitingGastrointestinal disorders2/2500/2480/2470/2430/244
Blood potassium decreasedInvestigations0/2500/2480/2471/2430/244
Blood sodium decreasedInvestigations0/2500/2480/2471/2430/244
Acute coronary syndromeCardiac disorders1/2500/2480/2471/2430/244
Myocardial infarctionCardiac disorders0/2500/2481/2471/2431/244
Iron deficiency anaemiaBlood and lymphatic system disorders0/2500/2480/2471/2430/244
Ischaemic strokeNervous system disorders0/2501/2481/2471/2430/244
Duodenal ulcer haemorrhageGastrointestinal disorders0/2500/2480/2471/2430/244
NephrolithiasisRenal and urinary disorders0/2500/2480/2471/2430/244
Most frequent other events
Most frequent other events
EventErtugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mg
HypoglycaemiaMetabolism and nutrition disorders12/25013/24811/2479/24320/244
Urinary tract infectionInfections and infestations20/25019/24813/24714/2438/244
NasopharyngitisInfections and infestations6/25013/2486/24712/24312/244

Baseline characteristics

The Baseline Analysis Population was the All-Participants-As-Treated population. One participant randomized to the Ertugliflozin 15 mg + Sitagliptin 100 mg arm did not receive study medication.

Age, Continuous
Age, Continuous(Years)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean55.1 ± 10.155.3 ± 9.554.8 ± 10.755.2 ± 10.455.1 ± 9.855.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Female12311493120118568
Male127134154123126664
Baseline Hemoglobin A1C (A1C)
Baseline Hemoglobin A1C (A1C)(Percent)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean8.6 ± 1.08.6 ± 1.08.5 ± 1.08.6 ± 1.08.6 ± 1.08.6 ± 1.0
Baseline Body Weight
Baseline Body Weight(Kilograms)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean88.6 ± 22.288.0 ± 20.389.8 ± 23.489.5 ± 20.887.5 ± 20.588.7 ± 21.5
Baseline Fasting Plasma Glucose
Baseline Fasting Plasma Glucose(mg/dL)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean184.1 ± 52.2179.5 ± 45.7177.4 ± 46.6183.8 ± 44.3177.2 ± 49.4180.4 ± 47.8
Static Beta-Cell Sensitivity to Glucose Index
Static Beta-Cell Sensitivity to Glucose Index(SBCSGI (10^-9min^-1))Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean20.9 ± 26.118.0 ± 16.320.2 ± 21.220.0 ± 16.619.3 ± 21.019.7 ± 20.5
Sitting Systolic Blood Pressure
Sitting Systolic Blood Pressure(mm Hg)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean129.7 ± 12.5128.9 ± 12.5128.3 ± 12.2130.2 ± 12.6129.1 ± 13.3129.3 ± 12.6
Baseline estimated glomerular filtration rate, eGFR
Baseline estimated glomerular filtration rate, eGFR(mL/min/1.73m^2)Ertugliflozin 5 mgErtugliflozin 15 mgSitagliptin 100 mgErtugliflozin 5 mg + Sitagliptin 100 mgErtugliflozin 15 mg + Sitagliptin 100 mgTotal
Mean91.9 ± 20.692.8 ± 21.492.6 ± 18.291.9 ± 20.492.6 ± 19.292.4 ± 20.0
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25. PubMed 29266675 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗
  • Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27. PubMed 32700393 ↗
  • Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9. PubMed 32648108 ↗
  • Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5. PubMed 32372382 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13. PubMed 32324082 ↗
  • Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13. PubMed 32324065 ↗
  • Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3. PubMed 31797522 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in May 2016, 25 months.

Results were first posted in Nov 2017, 1 year 5 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2014
First posted
Mar 28, 2014
StartActual
Apr 22, 2014
Primary completionActual
May 26, 2016
CompletionActual
May 26, 2016
Results first posted
Nov 1, 2017
Last update
Sep 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02099110
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 28, 2014
Start date
Apr 22, 2014
Primary completion
May 26, 2016
Completion
May 26, 2016
Results posted
Nov 1, 2017
Last update
Sep 12, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ertugliflozin · Sitagliptin

Start the discussion